Corrigendum to “miR-125a-5p Modulates Phenotypic Switch of Vascular Smooth Muscle Cells by Targeting ETS-1” (J. Mol. Biol. Jun 16 2017; 429(12):1817–1828) (S002228361730222X) (10.1016/j.jmb.2017.05.008);miR-125a-5p Modulates Phenotypic Switch of Vascular Smooth Muscle Cells by Targeting ETS-1

Journal of Molecular Biology

Volumn 429, Issue 12, 2017, Pages 1817-1828

  Gareri, C ^a,c   Iaconetti, C ^a   Sorrentino, S ^a   Covello, C ^a   De Rosa, S ^a   Indolfi, C ^a,b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b CNR   (Italy)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ETS 1; microRNAs; phenotypic switch; restenosis; vascular smooth muscle cells

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; MICRORNA; MICRORNA 125A 5P; MICRORNA 125B; PLATELET DERIVED GROWTH FACTOR BB; TRANSCRIPTION FACTOR ETS 1; TRANSGELIN; UNCLASSIFIED DRUG; ETS1 PROTEIN, RAT; MIRN125 MICRORNA, RAT;

ACTA2 GENE; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; CAROTID ARTERY; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE FUNCTION; GENE OVEREXPRESSION; GENE SWITCHING; GENE TARGETING; GENETIC TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; MALE; MYH11 GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; BIOSYNTHESIS; CELL DIFFERENTIATION; CELL MOTION; GENE EXPRESSION REGULATION; METABOLISM; PHYSIOLOGY; VASCULAR SMOOTH MUSCLE;

ANIMALS; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION; MICRORNAS; MUSCLE, SMOOTH, VASCULAR; PROTO-ONCOGENE PROTEIN C-ETS-1; RATS;

EID: 85019552531     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2017.07.013     Document Type: Erratum

References (61)

1. Lingman, M., Albertsson, P., Herlitz, J., Bergfeldt, L., Lagerqvist, B., The impact of hypertension and diabetes on outcome in patients undergoing percutaneous coronary intervention. Am. J. Med. 124 (2011), 265–275.
2. Williams, D.O., Holubkov, R., Yeh, W., Bourassa, M.G., Al-Bassam, M., Block, P.C., et al. Percutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute registries. Circulation 102 (2000), 2945–2951.
3. Fischman, D.L., Leon, M.B., Baim, D.S., Schatz, R.A., Savage, M.P., Penn, I., et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent restenosis study investigators. N. Engl. J. Med. 331 (1994), 496–501.
4. Kimura, T., Abe, K., Shizuta, S., Odashiro, K., Yoshida, Y., Sakai, K., et al. Long-term clinical and angiographic follow-up after coronary stent placement in native coronary arteries. Circulation 105 (2002), 2986–2991.
5. Joner, M., Finn, A.V., Farb, A., Mont, E.K., Kolodgie, F.D., Ladich, E., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 48 (2006), 193–202.
6. Curcio, A., Torella, D., Indolfi, C., Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. Circ. J. 75 (2011), 1287–1296.
7. Polimeni, A., De Rosa, S., Indolfi, C., Vascular miRNAs after balloon angioplasty. Trends Cardiovasc. Med. 23 (2013), 9–14.
8. Gomez, D., Owens, G.K., Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc. Res. 95 (2012), 156–164.
9. Indolfi, C., Torella, D., Coppola, C., Stabile, E., Esposito, G., Curcio, A., et al. Rat carotid artery dilation by PTCA balloon catheter induces neointima formation in presence of IEL rupture. Am. J. Physiol. Heart Circ. Physiol. 283 (2002), H760–H767.
10. Owens, G.K., Kumar, M.S., Wamhoff, B.R., Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev. 84 (2004), 767–801.
11. Alexander, M.R., Owens, G.K., Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease. Annu. Rev. Physiol. 74 (2012), 13–40.
12. Indolfi, C., Mongiardo, A., Curcio, A., Torella, D., Molecular mechanisms of in-stent restenosis and approach to therapy with eluting stents. Trends Cardiovasc. Med. 13 (2003), 142–148.
13. Regan, C.P., Adam, P.J., Madsen, C.S., Owens, G.K., Molecular mechanisms of decreased smooth muscle differentiation marker expression after vascular injury. J. Clin. Invest. 106 (2000), 1139–1147.
14. Corbett, S.J., Cosgrave, J., Melzi, G., Babic, R., Biondi-Zoccai, G.G., Godino, C., et al. Patterns of restenosis after drug-eluting stent implantation: insights from a contemporary and comparative analysis of sirolimus- and paclitaxel-eluting stents. Eur. Heart J. 27 (2006), 2330–2337.
15. Kitahara, H., Kobayashi, Y., Takebayashi, H., Nakamura, Y., Kuroda, N., Miyazaki, A., et al. Angiographic patterns of restenosis after sirolimus-eluting stent implantation. Circ. J. 73 (2009), 508–511.
16. Moussa, I., Leon, M.B., Baim, D.S., O'Neill, W.W., Popma, J.J., Buchbinder, M., et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 109 (2004), 2273–2278.
17. Rathore, S., Kinoshita, Y., Terashima, M., Katoh, O., Matsuo, H., Tanaka, N., et al. A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare metal stents and drug eluting stents. EuroIntervention 5 (2010), 841–846.
18. Stettler, C., Wandel, S., Allemann, S., Kastrati, A., Morice, M.C., Schomig, A., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370 (2007), 937–948.
19. Ambros, V., The functions of animal microRNAs. Nature 431 (2004), 350–355.
20. Wronska, A., Kurkowska-Jastrzebska, I., Santulli, G., Application of microRNAs in diagnosis and treatment of cardiovascular disease. Acta Physiol (Oxford) 213 (2015), 60–83.
21. Bartel, D.P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 (2004), 281–297.
22. De Rosa, S., Curcio, A., Indolfi, C., Emerging role of microRNAs in cardiovascular diseases. Circ. J. 78 (2014), 567–575.
23. Iaconetti, C., Gareri, C., Polimeni, A., Indolfi, C., Non-coding RNAs: the “dark matter” of cardiovascular pathophysiology. Int. J. Mol. Sci. 14 (2013), 19,987–20,018.
24. Gareri, C., De Rosa, S., Indolfi, C., MicroRNAs for restenosis and thrombosis after vascular injury. Circ. Res. 118 (2016), 1170–1184.
25. Latronico, M.V., Catalucci, D., Condorelli, G., Emerging role of microRNAs in cardiovascular biology. Circ. Res. 101 (2007), 1225–1236.
26. Liu, N., Olson, E.N., MicroRNA regulatory networks in cardiovascular development. Dev. Cell 18 (2010), 510–525.
27. Cordes, K.R., Sheehy, N.T., White, M.P., Berry, E.C., Morton, S.U., Muth, A.N., et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 460 (2009), 705–710.
28. Feng, C., Li, J., Ruan, J., Ding, K., MicroRNA-125a inhibits cell growth by targeting glypican-4. Glycoconj. J. 29 (2012), 503–511.
29. Jiang, L., Huang, Q., Zhang, S., Zhang, Q., Chang, J., Qiu, X., et al. Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. BMC Cancer, 10, 2010, 318.
30. Jiang, L., Huang, Q., Chang, J., Wang, E., Qiu, X., MicroRNA HSA-miR-125a-5p induces apoptosis by activating p53 in lung cancer cells. Exp. Lung Res. 37 (2011), 387–398.
31. Kim, S.W., Ramasamy, K., Bouamar, H., Lin, A.P., Jiang, D., Aguiar, R.C., MicroRNAs miR-125a and miR-125b constitutively activate the NF-kappaB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 7865–7870.
32. Shaham, L., Binder, V., Gefen, N., Borkhardt, A., Izraeli, S., MiR-125 in normal and malignant hematopoiesis. Leukemia 26 (2012), 2011–2018.
33. Torella, D., Iaconetti, C., Catalucci, D., Ellison, G.M., Leone, A., Waring, C.D., et al. MicroRNA-133 controls vascular smooth muscle cell phenotypic switch in vitro and vascular remodeling in vivo. Circ. Res. 109 (2011), 880–893.
34. Indolfi, C., Esposito, G., Di Lorenzo, E., Rapacciuolo, A., Feliciello, A., Porcellini, A., et al. Smooth muscle cell proliferation is proportional to the degree of balloon injury in a rat model of angioplasty. Circulation 92 (1995), 1230–1235.
35. Indolfi, C., Avvedimento, E.V., Di Lorenzo, E., Esposito, G., Rapacciuolo, A., Giuliano, P., et al. Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury. Nat. Med. 3 (1997), 775–779.
36. Dittmer, J., The biology of the Ets1 proto-oncogene. Mol. Cancer, 2, 2003, 29.
37. Dandre, F., Owens, G.K., Platelet-derived growth factor-BB and Ets-1 transcription factor negatively regulate transcription of multiple smooth muscle cell differentiation marker genes. Am. J. Physiol. Heart Circ. Physiol. 286 (2004), H2042–H2051.
38. Zhang, Y., Yan, L.X., Wu, Q.N., Du, Z.M., Chen, J., Liao, D.Z., et al. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res. 71 (2011), 3552–3562.
39. Wamhoff, B.R., Hoofnagle, M.H., Burns, A., Sinha, S., McDonald, O.G., Owens, G.K., A G/C element mediates repression of the SM22alpha promoter within phenotypically modulated smooth muscle cells in experimental atherosclerosis. Circ. Res. 95 (2004), 981–988.
40. Lacolley, P., Regnault, V., Nicoletti, A., Li, Z., Michel, J.B., The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Cardiovasc. Res. 95 (2012), 194–204.
41. Cheng, Y., Liu, X., Yang, J., Lin, Y., Xu, D.Z., Lu, Q., et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ. Res. 105 (2009), 158–166.
42. Merlet, E., Atassi, F., Motiani, R.K., Mougenot, N., Jacquet, A., Nadaud, S., et al. miR-424/322 regulates vascular smooth muscle cell phenotype and neointimal formation in the rat. Cardiovasc. Res. 98 (2013), 458–468.
43. Zampetaki, A., Mayr, M., MicroRNAs in vascular and metabolic disease. Circ. Res. 110 (2012), 508–522.
44. Iaconetti, C., De Rosa, S., Polimeni, A., Sorrentino, S., Gareri, C., Carino, A., et al. Down-regulation of miR-23b induces phenotypic switching of vascular smooth muscle cells in vitro and in vivo. Cardiovasc. Res. 107:4 (2015), 522–533.
45. Maegdefessel, L., Spin, J.M., Raaz, U., Eken, S.M., Toh, R., Azuma, J., et al. miR-24 limits aortic vascular inflammation and murine abdominal aneurysm development. Nat. Commun., 5, 2014, 5214.
46. Ji, R., Cheng, Y., Yue, J., Yang, J., Liu, X., Chen, H., et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ. Res. 100 (2007), 1579–1588.
47. Banerjee, S., Cui, H., Xie, N., Tan, Z., Yang, S., Icyuz, M., et al. miR-125a-5p regulates differential activation of macrophages and inflammation. J. Biol. Chem. 288 (2013), 35428–35436.
48. Hao, L., Wang, X.G., Cheng, J.D., You, S.Z., Ma, S.H., Zhong, X., et al. The up-regulation of endothelin-1 and down-regulation of miRNA-125a-5p, -155, and -199a/b-3p in human atherosclerotic coronary artery. Cardiovasc. Pathol. 23 (2014), 217–223.
49. Hultgardh-Nilsson, A., Cercek, B., Wang, J.W., Naito, S., Lovdahl, C., Sharifi, B., et al. Regulated expression of the ets-1 transcription factor in vascular smooth muscle cells in vivo and in vitro. Circ. Res. 78 (1996), 589–595.
50. Jovinge, S., Hultgardh-Nilsson, A., Regnstrom, J., Nilsson, J., Tumor necrosis factor-alpha activates smooth muscle cell migration in culture and is expressed in the balloon-injured rat aorta. Arterioscler. Thromb. Vasc. Biol. 17 (1997), 490–497.
51. Meredith, D., Panchatcharam, M., Miriyala, S., Tsai, Y.S., Morris, A.J., Maeda, N., et al. Dominant-negative loss of PPARgamma function enhances smooth muscle cell proliferation, migration, and vascular remodeling. Arterioscler. Thromb. Vasc. Biol. 29 (2009), 465–471.
52. Santulli, G., MicroRNAs and endothelial (Dys) function. J. Cell. Physiol. 231 (2016), 1638–1644.
53. Li, D., Yang, P., Xiong, Q., Song, X., Yang, X., Liu, L., et al. MicroRNA-125a/b-5p inhibits endothelin-1 expression in vascular endothelial cells. J. Hypertens. 28 (2010), 1646–1654.
54. Pan, Q., Liao, X., Liu, H., Wang, Y., Chen, Y., Zhao, B., et al. MicroRNA-125a-5p alleviates the deleterious effects of ox-LDL on multiple functions of human brain microvessel endothelial cells. Am. J. Phys. Cell Physiol. 312 (2017), C119–C130.
55. Wang, D., Deuse, T., Stubbendorff, M., Chernogubova, E., Erben, R.G., Eken, S.M., et al. Local microRNA modulation using a novel anti-miR-21-eluting stent effectively prevents experimental in-stent restenosis. Arterioscler. Thromb. Vasc. Biol. 35 (2015), 1945–1953.
56. Indolfi, L., Causa, F., Giovino, C., Ungaro, F., Quaglia, F., Netti, P.A., Microsphere-integrated drug-eluting stents: PLGA microsphere integration in hydrogel coating for local and prolonged delivery of hydrophilic antirestenosis agents. J. Biomed. Mater. Res. A 97 (2011), 201–211.
57. Santulli, G., Wronska, A., Uryu, K., Diacovo, T.G., Gao, M., Marx, S.O., et al. A selective microRNA-based strategy inhibits restenosis while preserving endothelial function. J. Clin. Invest. 124 (2014), 4102–4114.
58. Iaconetti, C., Sorrentino, S., De Rosa, S., Indolfi, C., Exosomal miRNAs in heart disease. Physiology (Bethesda) 31 (2016), 16–24.
59. Pan, Y., Jia, T., Zhang, Y., Zhang, K., Zhang, R., Li, J., et al. MS2 VLP-based delivery of microRNA-146a inhibits autoantibody production in lupus-prone mice. Int. J. Nanomedicine 7 (2012), 5957–5967.
60. Nam, D., Ni, C.W., Rezvan, A., Suo, J., Budzyn, K., Llanos, A., et al. Partial carotid ligation is a model of acutely induced disturbed flow, leading to rapid endothelial dysfunction and atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 297 (2009), H1535–H1543.
61. Indolfi, C., Torella, D., Cavuto, L., Davalli, A.M., Coppola, C., Esposito, G., et al. Effects of balloon injury on neointimal hyperplasia in streptozotocin-induced diabetes and in hyperinsulinemic nondiabetic pancreatic islet-transplanted rats. Circulation 103 (2001), 2980–2986.